Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial

Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial

IntroductionLive biotherapeutic products (LBPs) containing Lactobacillus crispatus may optimize the vaginal microbiota, reduce genital inflammation, and protect against HIV acquisition. Determining acceptability of LBPs among African women at high risk of HIV is essential to guide product developmen...

Full description

Saved in:
Bibliographic Details
Main Authors: A. Hemmerling, V. Govender, K. Dong, M. Dong, Sooseela Pillay, T. Ndung’u, A. Bhoola, J. Moodley, G. Casillas, L. Lagenaur, C. M. Mitchell, D. S. Kwon, C. R. Cohen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Reproductive Health
Subjects:
lower genital tract infections
prevention of HIV
vaginal microbiota
bacterial vaginosis
live biotherapeutic products
probiotics
Online Access:https://www.frontiersin.org/articles/10.3389/frph.2025.1544458/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/frph.2025.1544458/full

Similar Items